Invest in the future of drug optimization
INVEST IN THE FUTURE OF DRUG OPTIMIZATION
Virpax Pharmaceuticals is collaborating with the best research and development minds in the pharmaceutical industry. We are collaborating with these global drug development leaders, so we may improve how non-addictive post operative pain, severe pain, and CNS disorder medications are delivered.
As part of our ongoing non-dilutive funding strategy, Virpax will pursue US and ex-US sublicensing and co-development opportunities with strategic partners in human and animal healthcare. We will also continue to seek government and military grants and cooperation agreements.
- US Army Institute of Surgical Research (USAISR)
Awarded 5/05/2022 - National Center for Advancing Translational Sciences (NCATS)
Awarded 8/31/2020
Virpax engaged New England Investors to direct licensing strategy for Envelta™ in China.
Virpax engaged Destum Partners to seek global partners to sublicense OTC, Device, and Animal Health.
Partner with us as we develop and seek global approval for our next generation non-addictive pain and CNS disorder product candidates.
We can make a difference.
Investor News
BUSINESS INQUIRIES
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
610.727.4597
info@virpaxpharma.com
INVESTOR INQUIRIES
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
MEDIA INQUIRIES
Public Relations
Virpax Pharmaceuticals, Inc.
pr@virpaxpharma.com
